Innovative Product Offering C3 International’s flagship product, Idrasil, is a first-of-its-kind standardized cannabis pill focused on medical relief, presenting an opportunity to target health insurers, pharmacies, and healthcare providers interested in reimbursable and scientifically-backed cannabis therapeutics.

Sustainable Industry Position Operating within the rapidly expanding cannabinoid therapeutics sector, C3 International demonstrates growth potential through its focus on scientific research and medical applications, making it a compelling partner for organizations looking to expand into emerging wellness markets.

Strategic Advisory Network The company’s recent addition of influential industry advisors like Ken Shamrock and Gary Hall Jr. indicates an active approach to strengthening its market presence and credibility, opening avenues for collaborations with high-profile endorsers and strategic partners.

Market Expansion Potential With revenue estimates between 1M and 10M and a focus on healthcare compliance, C3 International is positioned to explore sales opportunities in medical institutions, insurance companies, and government programs that seek innovative and reimbursable cannabinoid therapies.

Tech-Driven Engagement Utilizing a modern tech stack including WordPress, cloud services, and SEO tools, C3 facilitates targeted online outreach and educational campaigns, providing opportunities for digital marketing partnerships and lead generation efforts aimed at healthcare professionals and patients.